Astra goes subcutaneous in its Merck race
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
Pfizer tries to banish the ghost of Celldex
A son of glembatumumab vedotin has just started its phase 1 study.
Nurix pushes its degrader forward
The company will start its confirmatory bexobrutideg study in June.
Fuelled by Pfizer, Triana enters the clinic
The industry’s first ALK degrader starts its first human study.
Revealed: Merck’s double bet on TROP2
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
